Platform
Inflammasome Inhibitor
A First-in-Class Platform Targeting Both the Initiation and Progression of Inflammation
GPCR19-based technology controls inflammatory responses across the skin, nervous, and respiratory systems.
Superior safety and efficacy are achieved compared with existing treatments.